医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

China Resources and Alpha Innomed Partner to Bring Med-Tech Innovations to Chinese Market

2021年07月15日 AM10:30
このエントリーをはてなブックマークに追加


 

SINGAPORE

China Resources (Shanghai) Medical Technology Co. Ltd. and Alpha Innomed Pte. Ltd. signed a memorandum of understanding on cooperating in the facilitation of technological, clinical, corporate and business development partnerships for international med-tech companies in China.

It is a key challenge for med-tech companies to bring their new and innovative products to the markets, in particular to those wide and distant markets, especially China. In order to enter a new market, there are many hurdles to overcome – regulatory requirements, distribution channel, market adoption, cultural differences, price competitiveness, etc. This is a long, risky and expensive journey for med-tech companies to find the right commercial partner on the right market for a fast landing, especially for small and medium sized companies. These medium and small sized innovative med-tech companies represent the majority of the industry and have a limited runway to succeed, both in funding and time.

The strategic partnership of China Resources (Shanghai) Medical Technology Co. Ltd. and Alpha Innomed Pte. Ltd. offers a strong platform for the med-tech companies to bring their innovative products to China. It encloses a deep insight into the needs of Chinese healthcare system and a path to identify the novel medical technologies which match those needs. It further incubates the selected products and leads them effectively and efficiently through the Chinese National Medical Products Administration certification process. Ultimately, the products will access the market, through the powerful medical device distribution network under the roof of China Resources to reach a full and fast sales success.

China Resources (Shanghai) Medical Technology Co. Ltd., a company under China Resources Pharmaceutical Commercial Group Medical Devices Co. Ltd., focuses on incubating and commercializing new medical devices on the Chinese Market.

Alpha Innomed Pte. Ltd., a Singapore and Switzerland dual-headquartered organization, devotes itself for accelerating the market reach for med-tech innovators through business digitalization and applicable intelligence.

China Resources: https://www.crpcg.com
Alpha Innomed: https://alpha-innomed.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005946/en/

CONTACT

Name: Dr. Joaquin Azpilicueta

Email: info@alpha-innomed.com

Phone: +65 8548 1610

同じカテゴリーの記事 

  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続
  • ReNAgade Therapeutics继续致力于GanNA Bio和糖生物学的研究
  • ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology